Crowell MBA Distinguished Speaker Series
Distinguished Speaker Series
- Monday, January 30, 2017
- 6–7:30 p.m.
- Business 109 - Moats Lecture Hall
- Open to: Alumni, Faculty, General Public, Parents, Staff, Students
Cost and Admission
This event is free to attend.
This series brings a selection of accomplished business leaders to campus to share their varied professional and personal insights, and provides the opportunity to network with fellow attendees including alumni, MBA mentors, faculty, and current and prospective MBA and MPAcc students. Light hors d'ouevres and dessert will be served after the event. This event is free and open to all.
Monday, January 30, 2017 6:00 - 7:30 p.m.
Biola University Crowell School of Business, Room 109
Ronnie Andrews, Founder and Principal of Bethesda Group
"Building a High Tech Company on Servant Leadership"
Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent.
Prior to this Ronnie held a number of other high profile executive roles including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in December 2010.
Ronnie is a passionate ambassador for the need for democratization of information into community based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He speaks regularly to industry groups and was selected as the Regional Winner for Ernst&Young’s Entrepreneur of the Year in 2011.
His current role is as founder and principal of the Bethesda Group, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace.
Contact Brenda Price at: